Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, Cash $134.9M
ABEO is trading near its 52-week low of $3.91 (2.6% above the low).
Summary
Abeona's Q3 showed ZEVASKYN revenue of $13.5 million (up 18% sequentially) and a narrowed $4.8 million net loss, with $134.9 million in cash before the separately announced $30 million PIPE. Treatment volume remains small at 15 patients since launch, and NTAP reimbursement became effective October 1.
Key Events · Earnings and Guidance · ABEO
-
Q3 ZEVASKYN Revenue $13.5M
Net ZEVASKYN revenue rose 18% sequentially to $13.5 million from $11.4 million in Q2 2026; one treatment's revenue was not recognized because the batch failed the identity assay release criterion.
-
Net Loss Narrows to $4.8M
Q3 net loss was $(4.8) million, or $(0.08) per share, versus $(20.2) million in Q2, aided by a $6.5 million non-cash gain on warrant liability remeasurement — not a cash inflow.
-
Cash $134.9M Before PIPE
Cash, equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30; the balance excludes the $30 million gross PIPE proceeds announced separately today.
-
Launch Volume Still Thin
15 ZEVASKYN treatments completed since launch, including six in Q3; the QTC network reached eight sites with four having completed treatments, and some patients may not reach biopsy slots until early 2027.
Analysis · ABEO · Life Sciences
The launch economics are the story in Abeona's first look at the third quarter. Revenue grew 18% sequentially to $13.5 million, while the net loss shrank to $4.8 million from $20.2 million in Q2, helped by a $6.5 million non-cash warrant remeasurement gain. Cash fell to $134.9 million from $146.8 million at June 30, before the $30 million PIPE that closed after quarter end. The commercial base is still thin: 15 treatments since launch, six in Q3, and eight qualified centers with only four having treated a patient. Management also flags that some patients in the pathway may not get biopsy slots until early 2027. NTAP reimbursement took effect October 1, which matters because Medicare beneficiaries are roughly 10% of RDEB patients.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.5M. The 52-week trading range was $3.91 to $7.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.